

# Thermo Fisher Scientific Inc.

US Satellite\*

Recommended since 08.11.2022

29.10.2024



<b>Country</b> US	<b>Market capitalization (bn)</b> USD 212,2	<b>Perf. since reco. (%)</b>
<b>Sector</b> Health Care	<b>Free float</b> 99,8%	Thermo Fisher Scientific Inc. 12,3
<b>Factset</b> TMO-US	<b>Closing price</b> USD 552,54	Sector 12,1
<b>ISIN</b> US8835561023	<b>ESG Risk score*</b> 12,7 Low risk	



**Profile**  
Thermo Fisher specialises in life science tools for research, medical analysis, environment, food safety. Four divisions: 1/ Laboratory Products & Biopharma Services (54% of sales): routine equipment for laboratories, contract development and manufacturing organization (CDMO); 2/ Life Sciences Solutions (23%): equipment for biological and medical research (sequencing, genetic analysis, BioProduction...); 3/ Analytical Instruments (17%): analytical instruments (chromatography, mass spectrometry, chemical analysis...) for the environment, food, research, industrial processes; 4/ Specialty Diagnostics (10%): diagnostic instruments/kits.

**Strengths/opportunities**

- Solid fundamentals, with structurally strong trends in health, food safety and environmental issues.
- Leading supplier, with the largest and most diversified range of instruments, consumables and services.
- Strong track record and diversified end markets.

**Weaknesses/threats**

- Academic research (15% of sales) is exposed to the risk of budgetary pressure. The Industrial part (<10%) is more cyclical.
- Sensitive to the evolution of R&D developments/expenditure.
- Competitive developments to be monitored, with market consolidation (still very fragmented) and technological evolutions.


**Investment case**

- The life science tools market is growing at 4-6%/year, driven by 1/ R&D investments in the biopharmaceutical sector, with a shift towards more equipment-intensive biological molecules/new generation therapies ; 2/ food safety and environmental monitoring ; 3/ the evolution of personalised medicine (targeted therapies), requiring genomic analysis ; and 4/ the expansion of the emerging markets. Thermo Fisher has become a key supplier with a wide range of instruments (18% of sales), consumables (60%) and services (22%). Present in the contract development and manufacturing organization (CDMO) space since 2017, this segment represents a growth area.
- The end markets are diversified, but with a predominant share of the biopharmaceutical sector (56% of turnover). The remaining 44% is divided between Academic Research, Industrial & Application (food safety and environmental control) and Diagnostics/Health.
- After six consecutive quarters of decline since the end of 2022, reflecting post-Covid normalization, Q3 sales were flat, confirming a sequential improvement (after -4% in Q1 and -1% in Q2). The 2024 targets (sales = \$42.4-43.3bn) imply a return to positive territory in Q4. The improving trend will continue into 2025, helped by a gradual recovery in business and a favorable basis for comparison. Organic growth should gradually return to the medium-term target of 7-9%.

**Valuation**

The valuation is reasonable, with a 2025 PE of 23.6x for EPS growth we expect to be 14%/year over 2024-28, i.e. a PEG (2024-28) of 1.69x.

**ESG risk vs. universe & sector (percentile)\***




USD	12/2023	12/2024e	12/2025e
Sales revenue (mio)	42 857	42 817	45 140
Sales growth	-4,6%	-0,1%	5,4%
EBIT adjusted (mio)	9 810	9 697	10 382
% of sales	22,9%	22,6%	23,0%
Net income (mio)	8 364	8 310	8 916
Net income growth	-8,7%	-0,6%	7,3%
FCF/Sales	16,2%	16,8%	18,8%
Net debt/Ebitda	2,6x	2,4x	1,8x
Dividend yield	0,3%	0,3%	0,3%
PE	25,6x	25,5x	23,4x
P/BV	4,6x	4,3x	4,0x


**ESG - risks and key points**

- Thermo Fisher's ESG risk level is low, due to low exposure, good management of ESG issues and strong corporate governance performance. The company has nevertheless encountered a moderate level of controversy in the past.
- Maintaining a high level of quality and safety of its products & services is essential to retain key clients and acquire new ones.

**5-year performance vs sector**



**Sales breakdown - 12/2023**



\*: see overleaf

Source: Factset, Sustainabilitycs

# Glossary

## Satellite

From 2015, B&Cie separates its investment recommendations into Core Holdings (higher organic growth potential, high free cash flow, ROCE in excess of the cost of capital and balance sheet efficiency throughout the cycle) and Satellite Recommendations, which do not meet the above criteria but are likely to outperform in the short-to-medium term.

## ESG Risk Score

At B&Cie, we take particular care to ensure that the companies in which we recommend investing are sustainable. Accordingly, our selection process takes account of risks relating to environmental, social and governance (ESG) issues. This approach is underpinned by research from Sustainalytics, the global leader in ESG and corporate governance analysis, whose methodology aims to identify major controversies and risks and assess a company's ESG risks relative to both its sector and the investment universe as a whole. The corresponding score is expressed as a percentile: the lower the overall risk score, the lower the risk within the investment universe.

## b-Digital, b-Transition & b-Well

Over and above the conventional geographical and sectoral approaches to asset management, at B&Cie we believe the world of tomorrow is being shaped by structural trends. We have identified three main megatrends: ongoing digital globalisation of the economy; economic transition, particularly in the energy sector; and the quest for wellness. We believe selecting and investing in companies that play an active role in these transformations should lead to more resilient portfolios that generate higher long-term returns. Our investment recommendations in the digital globalisation space are labelled "b-Digital", those in the economic transition space "b-Transition" and those in the wellness space "b-Well". A given recommendation may fall under more than one theme, in which case it will carry the relevant matching labels.

## Offices & Branches

### Bordier & Cie Genève

Rue Rath 16  
CH-1204 Genève  
Case postale  
CH-1211 Genève 3  
T + 41 58 258 00 00  
F + 41 58 258 00 40

### Bordier & Cie Berne

Spitalgasse 40  
Case postale  
CH-3001 Berne  
T + 41 58 258 07 00  
F + 41 58 258 07 10

### Bordier & Cie Nyon

Rue de la Porcelaine 13  
CH-1260 Nyon  
Case postale 1045  
CH-1260 Nyon 1  
T + 41 58 258 07 50  
F + 41 58 258 07 70

### Bordier & Cie Zurich

Talstrasse 83  
CH-8001 Zürich  
T + 41 58 258 05 00  
F + 41 58 258 05 50

### Bordier & Cie (France) S.A.

1, rue François 1er  
75008 Paris – France  
T + 33 1 55 04 78 78  
F + 33 1 49 26 92 48

### Bordier & Cie (Uruguay) S.A.

Edificio Beta 3, oficina 102  
Zonamerica  
91600 Montevideo  
Uruguay  
T + 598 2 518 2700  
F + 598 2 518 2703

### Bordier & Cie (Singapore) Ltd

CapitaGreen #14-00  
138 Market Street  
Singapore 048946  
T + 65 6239 9999  
F + 65 6239 9998

### Bordier Bank (TCI) Ltd

Leeward Highway  
Caribbean Place  
Providenciales  
Turks and Caicos  
T + 1 649 946 45 35  
F + 1 649 946 45 40

This document has been issued for information purposes and is exclusively supplied by Bordier & Cie SCmA in the framework of an existing contractual relationship with the recipient of this document. The views and opinions contained in it are those of Bordier & Cie SCmA. Its contents may not be reproduced or redistributed by unauthorized persons. The user will be held liable for any unauthorized reproduction or circulation of this document, which may give rise to legal proceedings. All the information contained in it is provided for information only and should in no way be taken as investment, legal or tax advice provided to third parties. Furthermore, it is emphasized that the provisions of our legal information page are fully applicable to this document and namely provisions concerning the restrictions arising from different national laws and regulations. Consequently, Bordier Bank does not provide any investment services or advice to "US persons" as defined by the Securities and Exchange Commission rules. Furthermore, the information on our website – including the present document – is by no means directed to such persons or entities.